Skip to content

Study · Observational study · n = 1,104 · 2006

3 results

Persistence with teriparatide in patients with osteoporosis: the UK experience.

Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA6 Jul 2006Cited by 50 (Europe PMC)

PMID16823543 (opens in a new tab)DOI10.1007/s00198-006-0171-5 (opens in a new tab)PepBankPUB-16823543
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyOther

    In UK patients with osteoporosis prescribed teriparatide, median treatment use was 252 days.

    In plain wordsIn UK patients with osteoporosis prescribed teriparatide, median use lasted 252 days.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableDuration of use
    Study

    n = 1,104

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated

    Measurements

    Median duration of use
    252 days
    all patients

    Source sentences

    Summary
    The median duration of use in all patients was 252 days.
    3 context sentences
    Summary · context
    A total of 1,104 patients were included in the analysis.
    Summary · context
    The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch.
    Summary · context
    Data was obtained to assess the start date, discontinuation date and reason for discontinuation in all patients receiving teriparatide since its launch.
  2. 02HumanObservational studySafety outcome

    In UK patients with osteoporosis prescribed teriparatide, 42 patients discontinued because of adverse events.

    In plain wordsIn UK patients with osteoporosis prescribed teriparatide, 42 patients stopped treatment because of adverse events.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableDiscontinuation due to adverse events
    Study

    n = 1,104

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Adverse event discontinuations
    42 patients
    teriparatide
    Adverse event discontinuation rate
    3.8%
    teriparatide

    Source sentences

    Summary
    Forty-two patients (3.8%) had discontinued treatment due to adverse events.
    3 context sentences
    Summary · context
    A total of 1,104 patients were included in the analysis.
    Summary · context
    The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch.
    Summary · context
    Data was obtained to assess the start date, discontinuation date and reason for discontinuation in all patients receiving teriparatide since its launch.
  3. 03HumanObservational studyOther

    Among UK teriparatide recipients at least 12 months after initiation, persistence was 87%.

    In plain wordsAmong UK patients prescribed teriparatide at least 12 months earlier, 87% continued treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicablePersistence at 12 months
    Study

    n = 435

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated

    Measurements

    Persistence
    87%
    patients at least 12 months after initiation

    Source sentences

    Summary
    Of the 435 patients who were at least 12 months post-initiation of treatment, persistence was 87%.
    2 context sentences
    Summary · context
    The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch.
    Summary · context
    Data was obtained to assess the start date, discontinuation date and reason for discontinuation in all patients receiving teriparatide since its launch.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT02472782

Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication

251 Hellenic Air Force & VA General Hospitaln = 851May 2015 to 15 Dec 2018

Osteoporosis, Postmenopausal · Osteoporosis, Steroid Induced

Trial pageClinicalTrials.govUpdated 10 Jan 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.